Table 3.

Frequency of diagnostic tests performed before and after age-specific testing recommendations

Test performed	All PALF participants (N=1144)		Total (N=658)		Phases 1 & 2 (N=515)				Phase 3 (N=143)				Age ≤ 90 days p-value	Age > 90 days p-value
					Age ≤ 90 days (n=78)		Age > 90 days (n=437)		Age ≤ 90 days (n=35)		Age > 90 days (n=108)
ANA, n %	678	59.3	380	57.8	8	10.3	282	64.5	1	2.9	89	82.4	0.27	0.0004
ASMA, n %	667	58.3	378	57.4	5	6.4	288	65.9	2	5.7	83	76.9	1.00	0.03
ALKM, n %	614	53.7	341	51.8	3	3.9	251	57.4	1	2.9	86	79.6	1.00	<0.0001
AI all 3, n %	559	48.9	309	47.0	2	2.6	227	52.0	1	2.9	79	73.1	1.00	<0.0001
HSV*, n %	426	37.2	306	46.5	36	46.2	183	41.9	26	74.3	61	56.5	0.006	0.006
Enterovirus*, n %	155	13.5	138	21.0	12	15.4	49	11.2	29	82.9	48	44.4	<0.0001	<0.0001
Serum AA, n %	412	36.0	265	40.3	45	57.7	127	29.1	27	77.1	66	61.1	0.047	<0.0001
Acylcarnitine profile, n %	358	31.3	247	37.5	37	47.4	111	24.4	23	65.7	76	70.4	0.07	<0.0001
Urine succinylacetone,	249	21.8	154	23.4	42	53.9	69	15.8	24	68.6	19	17.6	0.14	0.65
Hepatitis A, n %	785	68.6	465	70.7	35	44.9	330	75.5	9	25.7	91	84.3	0.054	0.052
Hepatitis B, n %	893	78.1	525	79.8	43	55.1	374	85.6	14	40.0	94	87.0	0.14	0.70
Ferritin, n %	476	41.6	256	38.9	43	55.1	133	30.4	26	74.3	54	50.0	0.054	0.0001
Ceruloplasmin*, n %	538	47.0	332	50.5	5	6.4	257	58.8	2	5.7	68	63.0	1.00	0.43
Urine copper, n %	195	17.0	99	15.0	0	0.0	74	16.9	0	0.0	25	23.1	--	0.13
Lactate, n %	751	65.6	398	60.5	54	69.2	218	49.9	31	88.6	95	88.0	0.03	<0.0001
Pyruvate, n %	254	22.2	213	32.4	31	39.7	93	21.3	22	62.9	67	62.0	0.02	<0.0001
Lactate/Pyruvate on same day, n %	225	19.7	187	28.4	27	34.6	77	17.6	20	57.1	63	58.3	0.03	<0.0001
Acetaminophen level, n %	487	42.6	325	49.4	8	10.3	231	52.9	4	11.4	82	75.9	1.00	<0.0001

^*There was less viral and ceruloplasmin testing in Phase 1 than in Phase 2.

BOLD: Expected to increase based on recommended age-specific diagnostic tests. ITALICS: Expected to decrease based on recommended age-specific diagnostic tests